US Patent 9,181,632: Claims, Validity Risk, and US Landscape for Crystalline Bezlotoxumab Fab Toxin B Complex
What does US 9,181,632 actually claim?
US 9,181,632 is directed to a specific crystalline complex and a crystallization method built around a defined protein-protein complex: a bezlotoxumab Fab fragment complexed to a C. difficile toxin B polypeptide spanning amino acids 1834 to 2101 (the claim states “C. difficile toxin B amino acids 1834-2101”).
The patent’s legal scope is narrow in one sense (crystal form and coordinates are specified), and broad in another sense (any “isolated crystal” of the specified complex with the specified crystal parameters can fall within the claims even if prepared by different routes).
Core claim elements (from the provided claim text)
Claim 1 (product-by-structure and crystal form)
- Protein complex: “isolated crystal comprising”:
- Bezlotoxumab Fab fragment
- Complexed to a polypeptide comprising SEQ ID NO: 14
- SEQ ID NO: 14 is C. difficile toxin B amino acids 1834 to 2101
- Crystal characterization:
- Space group: P21
- Unit cell dimensions:
- a = 79.413 Å
- b = 134.659 Å
- c = 102.579 Å
- α = γ = 90°
- β = 112.559°
Claim 2 (product with structural similarity metric)
- Adds an RMSD constraint:
- “RMSD of conserved residue backbone atoms of less than about 2.0 angstroms”
- when superimposed on backbone atoms “described by structural coordinates of Table 1.”
Claim 3 (method: specific crystallization recipe)
- Producing the crystalline complex of claim 1 by incubating:
- First solution: 10 mg/mL of the complex; 5 mM phosphate pH 7.4; 68.5 mM NaCl; 1.35 mM KCl; 2.2% PEG 4000
- sealed container in close proximity to:
- Second solution: 4.4% PEG 4000
- This is a classic two-solution vapor diffusion style setup, with explicit salt and PEG concentrations.
Claim 4 (method: physical configuration of the drop)
- First solution is a drop that is “hanging or sitting on a surface.”
What the claim construction implies for coverage
- The patent uses crystallographic identifiers (space group + unit cell) as a gate.
- It uses sequence-to-structure linkage (SEQ ID NO: 14 corresponds to toxin B aa 1834-2101) to limit the toxin segment.
- It uses an RMSD threshold in claim 2 that can cut out variant crystal structures that differ in conserved backbone alignment above the 2 Å tolerance.
- Method claims 3 and 4 are tied to a specific crystallization formulation and a drop configuration, which may limit enforceability against crystallizations done with different PEG concentrations, different buffer strengths/salts, or different container geometry.
Is the “crystal characterized by P21 and unit cell” claim vulnerable to indefiniteness or overbreadth?
The risk is not “definiteness” in the abstract; it is the practical enforceability of a claim that hinges on crystallographic parameters.
Why enforceability can be harder than it looks
-
Crystal screening can yield multiple polymorphs
- For protein complexes, crystallization conditions often generate different lattice packings. A competitor may produce a different crystal form of the same complex where:
- space group is different, or
- unit cell constants differ outside measurement tolerance, or
- the RMSD constraint in claim 2 is not met.
-
Measurement variability
- Unit cell parameters depend on data quality, temperature, indexing choices, and refinement strategy. If a later accused crystal is close but not identical, the fight shifts to instrument-based and analysis-based comparisons, not just the biochemical identity of the complex.
-
Claim 1 is product scope, but derived from characterization
- Claim 1 reads like a “crystal form” claim, but it is not limited by “prepared by” a method. That increases coverage for third parties who incidentally or intentionally obtain the same crystal form via different methods, but it also increases evidentiary burden: the patent owner must demonstrate the accused crystal meets the same lattice identifiers.
Overbreadth vs. narrowness
- Narrowness: The claim is limited to one segment of toxin B (aa 1834-2101) and to one crystal form (P21 with exact unit cell).
- Potential overbreadth: If “isolated crystal” is interpreted broadly, a competitor extracting only a few crystals (without producing bulk crystals) could still infringe if the crystals match the lattice.
How strong is novelty likely to be over prior art?
Without the file wrapper and without the patent text beyond the claim excerpt, the novelty assessment must be anchored on what a prior art search would target: crystal structures of antibody or Fab complexes with C. difficile toxin B, and crystallization conditions that produce defined lattice forms.
Still, the claims themselves define the novelty candidate with tight focus:
- bezlotoxumab Fab + toxin B aa 1834-2101 segment
- a P21 lattice with specific unit cell dimensions
- an RMSD alignment to Table 1 coordinates below 2.0 Å for conserved backbone residues
- explicit crystallization recipe (PEG 4000 2.2% in the protein drop; 4.4% PEG 4000 in the reservoir; specific salts and buffer)
The likely prior-art “attack surfaces”
-
Any earlier structure for bezlotoxumab Fab with toxin B
- If prior art discloses a structure of the complex with enough overlap, novelty weakens, especially for claim 1.
- The claim’s crystal form identifiers can still preserve novelty even if an earlier structure exists, unless the earlier work generated the same lattice.
-
Same complex but different toxin segment boundaries
- If earlier structures use a different toxin B fragment (different start or end residue), claim 1 retains novelty, because SEQ ID NO: 14 is tied to aa 1834-2101.
-
Same complex and same segment, but different crystal polymorph
- Prior art that discloses crystallization of the complex does not automatically anticipate claim 1 unless the same crystal form (P21 + unit cell) is disclosed.
-
Method novelty
- Claim 3 uses a crystallization recipe that is plausible and common in protein crystallography. Anticipation risk increases if the same (or substantially the same) recipe appears in earlier crystallography protocols for the same complex.
Where is the biggest invalidity leverage: anticipation or obviousness?
The claims contain multiple layers that can trigger different invalidity pathways.
Anticipation (strongest when a single reference discloses the same crystal form)
- Claim 1: If a prior publication or structure database entry shows the identical complex (bezlotoxumab Fab + toxin B aa 1834-2101) and reports space group P21 and the same unit cell (within reported precision), claim 1 is vulnerable to anticipation.
- Claim 2: If structural coordinates comparable to “Table 1” are available and the RMSD <2.0 Å constraint is inherently met by the earlier structure, claim 2 also weakens.
- Claim 3 and 4: Anticipation is possible if a prior art source gives the same protein complex, then provides the same crystallization formulation and drop/reservoir geometry.
Obviousness (strongest when multiple references combine to reach the same crystal)
Even if no single reference reports the exact lattice, examiners and challengers can frame obviousness based on:
- known crystallization approaches for antibody Fab-protein complexes,
- PEG-salt vapor diffusion practices,
- and known structure production workflows.
However, obviousness is often harder when a claim is anchored to specific lattice parameters. A challenger must show why a skilled person would reasonably expect the same P21 lattice with those unit cell dimensions from the referenced combination, not just “a crystal.”
What does the method claim likely cover, and what can still avoid it?
Claim 3: formulation and proximity conditions are limiting
Claim 3 requires:
- 10 mg/mL complex
- phosphate pH 7.4 (5 mM)
- 68.5 mM NaCl
- 1.35 mM KCl
- 2.2% PEG 4000 in the protein drop
- close proximity to a second solution with 4.4% PEG 4000
- sealed container
Claim 4: drop on a surface vs hanging
Claim 4 narrows to the first solution being in drop form “hanging or sitting” on a surface.
Common design-arounds
A party can attempt non-infringement by changing any of these elements:
- buffer system or pH outside the claimed phosphate pH 7.4 condition
- PEG 4000 concentration in the drop (2.2%) or reservoir (4.4%)
- ionic strength via different NaCl/KCl concentrations
- altering the crystal growth setup so that the “close proximity” and vapor diffusion relationship differs in a technically meaningful way
- using different protein concentration
Even if the crystallization yields the same lattice, changing those explicit conditions can reduce method infringement risk, but does not eliminate product claim risk if they still obtain crystals matching claim 1’s lattice.
How does the crystallization recipe relate to what’s likely taught in the field?
The PEG 4000 vapor diffusion framework with low millimolar buffer and moderate salt is standard in protein crystallography. That means:
- Claim 3 may face obviousness pressure on the general recipe level.
- But claim 3 is not “general”; it is the exact recipe with explicit concentrations.
Obviousness will then hinge on whether prior art taught that this exact composition produces crystals of this exact complex (with the claim 1 crystal form), not just crystals generally.
How to map the US patent landscape around this specific claim type
A practical landscape assessment for US 9,181,632 depends on whether there are:
- US patents on bezlotoxumab,
- US patents on structures/complexes of toxin B fragments,
- and US patents directed to crystallization methods for antibody-toxin complexes.
For this analysis, the claim text itself indicates the patent is likely part of a structural biology IP cluster: “crystal form + coordinates” plus crystallization conditions.
Landscape “nodes” most likely to matter
-
Antibody and fragment IP
- bezlotoxumab and its Fab fragments are typically covered by earlier antibody composition and engineered binding claims (usually with broad functional coverage).
- Those do not necessarily anticipate the crystal-lattice claims, but they can affect design-around feasibility.
-
Toxin B fragment definition
- Claim 1 ties to toxin B aa 1834-2101. Any patents or papers defining toxin B fragments used for neutralization or binding are relevant because they determine whether SEQ ID NO: 14 is already disclosed for structural studies.
-
Structure deposition and crystallographic reports
- If a structure has been deposited and publicly reported with the same lattice identifiers, that is often the highest-impact novelty threat.
-
Crystallization method patents
- If prior art gives the same PEG buffer-salt pairing for this complex, claim 3’s novelty and obviousness profile weakens.
Critical consequence for investors and R&D leaders
- If the landscape already contains a disclosed structure for the same complex and crystal form, the patent’s value shifts from enforcement against structure-production to leverage in licensing or settlement.
- If only the complex (or only toxin fragment binding) is in the prior art, then claim 1 remains the strongest barrier, because competitors must hit the same lattice metrics.
What are the key enforcement and litigation pressure points?
Claim 1 evidence burden
To enforce claim 1 against an accused crystal, the patent owner must show:
- the complex involves bezlotoxumab Fab and toxin B aa 1834-2101
- the accused sample produces a crystal with:
- space group P21
- unit cell matching the claimed values
- claim 2 adds the RMSD <2.0 Å requirement relative to Table 1 conserved backbone residues
This typically requires crystallography data and careful structural comparison. That can raise litigation costs and narrow the set of infringing activities.
Method claims may be easier to avoid but harder to prove
Method infringement requires showing the accused party used the specific formulation and setup. Competitors can:
- change recipe parameters slightly, or
- use different crystallization formats,
reducing method infringement risk.
But again, that does not protect against claim 1 if they still obtain crystals matching the lattice.
Key Takeaways
- Claim 1 is the core asset: product protection for a very specific bezlotoxumab Fab-toxin B fragment complex presented as a crystal with space group P21 and unit cell a=79.413 Å, b=134.659 Å, c=102.579 Å, β=112.559°.
- Claim 2 tightens structural identity via an RMSD threshold (<2.0 Å) against “Table 1” conserved backbone coordinates.
- Claims 3 and 4 are recipe-limited crystallization method claims tied to PEG 4000 2.2% in the protein drop and 4.4% PEG 4000 in the reservoir, plus exact buffer/salt and drop format.
- Invalidity leverage is highest if any prior art discloses the same complex and crystal lattice (anticipation), or if prior art provides a strong rationale that the exact lattice is expected (obviousness). The lattice specificity increases the “hit rate” needed for anticipation but also makes enforcement more evidentiary.
- Design-around strategy differs by claim type: method changes may avoid claims 3-4, while crystal-form differences are the real escape from claim 1-2.
FAQs
-
What part of toxin B does the patent lock in?
Amino acids 1834-2101 (SEQ ID NO: 14) of C. difficile toxin B.
-
What crystal form does claim 1 require?
Space group P21 with unit cell: a=79.413 Å, b=134.659 Å, c=102.579 Å, α=γ=90°, β=112.559°.
-
Does claim 1 protect the method used to make the crystals?
No. It protects the isolated crystal form; method claims are in claims 3-4 separately.
-
What does claim 2 add beyond claim 1?
A structural alignment limit: RMSD of conserved residue backbone atoms < about 2.0 Å versus Table 1 coordinates.
-
What are the main variables that could avoid claim 3?
Deviating from the exact crystallization recipe: the PEG 4000 concentrations, buffer/salt composition, and the sealed close-proximity setup, plus the drop configuration in claim 4.
References
[1] United States Patent and Trademark Office. US 9,181,632 (claims as provided in the prompt).
